Abstract
Recently new radiopharmaceuticals have been proposed for investigating prostate cancer patients, including metabolic radiotracer such as anti1-amino-3-18F-fluorocyclobutane-1-carboxylic acid (18F-FACBC) or probe targeting the prostate-specific membrane antigen (PSMA). These radiotracers showed in literature better performance in the detection of prostate cancer recurrence as compared to choline PET/CT imaging [1, 2].
Cite
CITATION STYLE
Ceci, F., Morigi, J. J., Zanoni, L., & Fanti, S. (2016). New radiopharmaceutical markers for metabolism and receptor. In Bone Metastases from Prostate Cancer: Biology, Diagnosis and Management (pp. 95–104). Springer International Publishing. https://doi.org/10.1007/978-3-319-42327-2_9
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
